Andy Kidd

Andy Kidd

Company: Aptinyx

Job title: Chief Operating Officer


Mr. Kidd is chief operating officer of Aptinyx. Prior to joining Aptinyx, he was with Baxter International for over ten years, most recently as senior vice president of strategy and business development. He also held a number of commercial leadership positions including general manager of Baxter Canada, global franchise head for surgical care, and general manager of US anesthesia and cardiovascular. Before joining Baxter he worked at The Boston Consulting Group focused on pharmaceutical and healthcare clients. Mr. Kidd received a BM BCh medical degree from the University of Oxford and a BA in medical sciences from the University of Cambridge.


Live Q&A 12:10 pm

Read more

day: Day Two

BNC210: A Negative Allosteric Modulator of Alpha7 Nicotinic Acetylcholine Receptor in Development for the Treatment of Anxiety, Depression & Post Traumatic Stress Disorder 11:30 am

• Why is this novel target relevant for treatment of anxiety, depression and PTSD? • Clinical data demonstrating target engagement from EEG studies and proof-ofbiology in healthy subjects • Combination of imaging and behavioral studies in GAD patients comparing with lorazepam • PTSD pharmacometric analysis • Defining the path forwardRead more

day: Day Two

Pioneering Novel Therapeutic Approaches to Address PTSD 11:10 am

• Exploring NYX-783: an NMDA receptor modulating small molecule in Phase 2 clinical development as a therapy for post-traumatic stress disorder • Development of drugs that facilitate a more rapid extinction of a trauma response, acting on the underlying learning and memory dysfunction that exists in PTSD • How NYX-783 has demonstrated robust and long-lasting…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.